Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24698707 | 0.83 | CHRNB2 (0.37) | CYP1A2HIF1ASLC6A3CHRNB2CHRNB4 | |
| SCHEMBL5896943 | 0.80 | SLC6A2 (0.36) | CYP1A2HIF1ASLC6A3CHRNB2CHRNB4 | |
| SCHEMBL5897600 | 0.79 | SLC6A2 (0.38) | CYP1A2HIF1ASLC6A3CHRNB2CHRNB4 | |
| SCHEMBL5897643 | 0.72 | SLC6A3 (0.35) | CYP1A2HIF1ASLC6A3CHRNB2CHRNB4 | |
| SCHEMBL3813730 | 0.70 | SLC6A2 (0.36) | CYP1A2HIF1ASLC6A3ALDH1A1 | |
| SCHEMBL10353154 | 0.69 | CHRNB2 (0.47) | CYP1A2SLC6A3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13595119 | 0.69 | CHRM2 (0.43) | CYP1A2CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6559191 | 0.69 | CYP1A2 (0.36) | CYP1A2HIF1ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13882832 | 0.68 | CYP1A2 (0.46) | CYP1A2HIF1ACHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10612580 | 0.68 | CHRNB2 (0.46) | CYP1A2SLC6A3CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038087-B2 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040063999-A1 | Process for the production of optically active amino alcohols | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1398310-A1 | Process for the production of optically active amino alcohols | Takasago International Corporation (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063999-A1 | Process for the production of optically active amino alcohols | ADH1C, ADH1A, ADH5 | CYP1A2 296/4885HIF1A 2117/4885SLC6A3 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.